Phathom Pharmaceuticals, Inc. (PHAT): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of PHAT were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Phathom Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PHAT
161 funds and institutions reported PHAT shares worth $786M at the end of Q2 2026, about 91% of the company. The largest holder is Frazier Life Sciences Management, L.P. with 15.6%.
Funds and institutions (13F) 91%Everyone else 9%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12.47M | 15.63% | $135M | No change |
| Medicxi Ventures Management (Jersey) Ltd | 7.46M | 9.36% | $81M | No change |
| BlackRock, Inc. | 4.53M | 5.67% | $49.1M | +11% |
| Invesco Ltd. | 4.03M | 5.05% | $43.7M | -7% |
| Carlyle Group Inc. | 3.50M | 4.38% | $37.9M | No change |
| Millennium Management LLC | 3.38M | 4.23% | $36.6M | -16% |
| Vanguard Capital Management LLC | 2.66M | 3.33% | $28.8M | +3% |
| GW&K Investment Management, LLC | 2.17M | 2.72% | $23.5M | +52% |
| Franklin Resources Inc | 1.97M | 2.47% | $21.4M | +98% |
| NEA Management Company, LLC | 1.96M | 2.46% | $21.3M | No change |
| 683 Capital Management, LLC | 1.85M | 2.32% | $20.1M | No change |
| Goldman Sachs Group Inc | 1.78M | 2.23% | $19.3M | +184% |
| State Street Corp | 1.59M | 1.99% | $17.2M | +14% |
| Catalys Pacific, LLC | 1.49M | 1.87% | $16.2M | No change |
| Nomura Asset Management International Inc. | 1.46M | 1.83% | $15.9M | +21% |
| Geode Capital Management, LLC | 1.32M | 1.65% | $14.3M | -1% |
| Wasatch Advisors LP | 1.31M | 1.64% | $14.2M | -3% |
| Ensign Peak Advisors, Inc | 1.05M | 1.32% | $11.4M | -35% |
| Propel Bio Management, LLC | 1.05M | 1.32% | $11.4M | +25% |
| Point72 Asset Management, L.P. | 1.02M | 1.28% | $11.1M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No PHAT insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PHAT short interest
High short interest. 11.3% of PHAT shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 11%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.20M PHAT shares were sold short, 11.3% of the shares outstanding, down 5.9% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 4.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.20M | 11.32% | -6% | 1.90M | 4.8 |
| Oct 15, 2026 | 9.78M | 12.09% | -3% | 1.41M | 6.9 |
| Sep 30, 2026 | 10.11M | 12.50% | -0% | 1.37M | 7.4 |
| Sep 15, 2026 | 10.16M | 12.56% | -6% | 1.11M | 9.1 |
| Aug 31, 2026 | 10.82M | 13.38% | -8% | 983,432 | 11.0 |
| Aug 14, 2026 | 11.77M | 14.55% | -12% | 1.71M | 6.9 |
| Jul 31, 2026 | 13.33M | 16.47% | +10% | 1.53M | 8.7 |
| Jul 15, 2026 | 12.12M | 15.20% | +1% | 1.35M | 9.0 |
| Jun 30, 2026 | 11.99M | 15.04% | +7% | 1.03M | 11.7 |
| Jun 15, 2026 | 11.16M | 14.00% | +8% | 1.08M | 10.4 |
| May 29, 2026 | 10.35M | 12.98% | +1% | 1.10M | 9.4 |
| May 15, 2026 | 10.29M | 12.90% | +6% | 1.19M | 8.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Phathom Pharmaceuticals company events
Phathom Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Oct 26, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration’s establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application referencing VOQUEZNA… Filing
- Oct 23, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced that BDR Pharmaceuticals International Pvt. Filing
- Sep 29, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive Gastroesophageal Reflux Disease, or… Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 23, 2026AnnouncementPhathom Pharmaceuticals, Inc. announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA ® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis in adults. Filing
- May 21, 2026VoteReported shareholder vote results. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementPhathom Pharmaceuticals, Inc. entered into an underwriting agreement with Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, relating to the issuance and sale of (i) 6,875,000 shares of the Company’s common stock, par value $0.0001… Filing
- Jan 7, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Phathom Pharmaceuticals financials
Famous investors that hold PHAT
5 of the 50 well-known investors we track reported holding PHAT in their latest 13F filing. The largest position is Israel Englander's, worth $17.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 2.40M | $17.5M | 0.0% | -29% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.50M | $11M | 0.0% | +47% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 343,670 | $2.5M | 0.0% | +86% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 21,909 | $160K | 0.0% | -90% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 16,530 | $121K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PHAT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 0.0% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 0.0% |
| Nov 2, 2026 | Frazier Life Sciences Public Fund, L.P. | 13D/A | 6.5% |
| Nov 2, 2026 | Frazier Life Sciences Public Fund, L.P. | 13D/A | 6.5% |
Questions about Phathom Pharmaceuticals, Inc. (PHAT) stock
Who owns the most PHAT stock?
The largest reported owner of Phathom Pharmaceuticals, Inc. (PHAT) is Frazier Life Sciences Management, L.P., with 15.6% of the company. In total, 161 funds and institutions reported holding PHAT at the end of Q2 2026, together about 91% of the shares. See the largest owners.
Are PHAT insiders buying or selling?
No PHAT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in PHAT?
As of Oct 30, 2026, 9.20M PHAT shares were sold short, 11.3% of the shares outstanding, down 5.9% from the report before. At the average daily volume of 1.90M shares, buying them all back would take about 4.8 trading days (days to cover). See the history.
Which famous investors hold PHAT?
5 of the 50 well-known investors we track reported PHAT in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $17.5M. See all holders.
Executive pay
Phathom Pharmaceuticals's chief executive was paid a total of $3.6M for the year ended Dec 31, 2024, up 5% from $3.4M the year before. In the last 12 months, Phathom Pharmaceuticals's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.